Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Glecaprevir and Pibrentasvir Clear all

Conditions: Kidney Failure, Hepatitis C, Kidney Disease, Chronic
Interventions: Glecaprevir and Pibrentasvir; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C Infection, HIV Infection
Interventions: Glecaprevir/Pibrentasvir (G/P); Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 11
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 6 more

Conditions: Heart Failure
Interventions: Transplant with HCV positive donor, followed by surveillance and treatment of viremia; Combination Product
Lead sponsor: NYU Langone Health; Other
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of
Interventions: glecaprevir/pibrentasvir (GLE/PIB); Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: End Stage Renal Disease, Chronic Hepatitis c
Interventions: Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 34 Years to 44 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C, Chronic
Interventions: glecaprevir (300mg)/pibrentasvir (120mg); Drug
Lead sponsor: Kirby Institute; Government
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Durham, North Carolina + 1 more

Conditions: Kidney Failure, Kidney Diseases, Hepatitis C
Interventions: glecaprevir/pibrentasvir tablets; Drug
Lead sponsor: Raymond T. Chung, MD; Other
Eligibility: 30 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 15
States / cities: San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more

Conditions: End Stage Renal Disease, Hepatitis C
Interventions: 300mg glecaprevir/pibrentasivir 120mg; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis C, Addict Heroin
Interventions: Glecaprevir-pibrentasvir; Drug
Lead sponsor: Id Care; Other
Eligibility: 18 Years to 30 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Hillsborough, New Jersey

Conditions: Hepatitis C
Interventions: Mavyret; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Kidney Transplant, Hepatitis C, HCV
Interventions: Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hepatitis C, Pregnancy Complications
Interventions: Glecaprevir-pibrentasvir; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: St Louis, Missouri

Conditions: Hepatitis C
Interventions: Cepheid POC HCV Viremia (RNA) test, HCV education from a health care provider, Glecaprevir and Pibrentasvir; Diagnostic Test · Other · Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Long Island City, New York • New York, New York

Conditions: End Stage Renal Disease, Hepatitis C
Interventions: Glecaprevir/pibrentasvir; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Opioid Use, Opioid Use Disorder, Risk Reduction, Hiv, Hepatitis C
Interventions: Suboxone, Truvada, Mavyret; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Durham, North Carolina • Greensboro, North Carolina

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/Pibrentasvir; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: San Diego, California • San Francisco, California • West Hollywood, California + 2 more

Conditions: Hepatitis C, Chronic, Nonadherence, Patient
Interventions: Digital Medicine; Device
Lead sponsor: Proteus Digital Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 16
States / cities: Birmingham, Alabama • San Francisco, California • Colorado Springs, Colorado + 12 more

Conditions: Hepatitis C Virus Infection
Interventions: Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 99 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 8
States / cities: Dothan, Alabama • Los Angeles, California • Baltimore, Maryland + 5 more

Conditions: Hepatitis C Virus (HCV)
Interventions: Glecaprevir/pibrentasvir; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 11
States / cities: La Jolla, California • Pasadena, California • Tampa, Florida + 7 more

Conditions: Cardiovascular Diseases, Hepatitis C, Hiv
Interventions: Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI; Drug · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: HCV Infection
Interventions: Glecaprevir/pibrentasvir; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: ESRD
Interventions: Glecaprevir/pibrentasvir; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C
Interventions: ABT-493, ABT-530; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 20
States / cities: Dothan, Alabama • Bakersfield, California • Coronado, California + 14 more

Search by objective public record fields.

QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir

Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

HCV Positive Heart Donors

Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients

Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors

Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study

A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret

Utilization of Hepatitis C Positive Kidneys in Negative Recipients

Feasibility and Acceptability of HCV Treatment in Pregnancy

HCV Test and Treat Utilizing Simplified HCV Patient Education

Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors

Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection

Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment

Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication

Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)

A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530